Proliant obtains GRAS status for ImmunoLin

March 12, 2009

Proliant Health and Biologicals has announced self-affirmed GRAS status for the company’s proprietary, trademarked ingredient ImmunoLin (bovine globulin concentrate). According to the FDA’s letter, “Based on the information provided by Proliant, as well as other information available to FDA, the agency has no questions at this time regarding Proliant's conclusion that bovine globulin is GRAS under the intended conditions of use.”

“The market for food and nutrition products that support gut health and immunity are expanding rapidly,” said Eric Weaver, Proliant Chief Scientific Officer. “The formal approval allows the use of ImmunoLin in products requiring GRAS such as functional foods and beverages, meal replacement, and medical foods.”

Proliant release

FDA letter